
## FY 2021 RESULTS




# **CHRISTOPHE PERILLAT**CEO






#### **OUTPERFORMANCE**

2021 vs 2020





\*IHS as of February 14, 2022/CPCA estimates for China




#### **OEM sales by production region**


% of OEM sales





#### % of OEM sales







#### **GROSS MARGIN BREAKDOWN**



Gross R&D expenditure In €m & as a % of sales



## Capitalized development expenditure In €m and as a % of sales



| H2 2020                 | H2 2021                   | _                       | In million of euros and as a % of sales                    | FY 2020            | FY 2021           | _               |
|-------------------------|---------------------------|-------------------------|--|--------------------|-------------------|-----------------|
| (798)<br>(8.5)%         | (8 <b>53</b> )<br>(10.3)% | + <b>7</b> %<br>+180bps | Gross Research and Development expenditure As a % of sales | (1,660)<br>(10.1)% | (1,704)<br>(9.9)% | +3%<br>-20bps   |
| (20)                    | 6                         | -97%                    | IFRS impact  | (132)              | 52                | na              |
| 51                      | 93                        | +82%                    | Subsidies and grants, and other income                     | 97                 | 142               | +46%            |
| ( <b>767)</b><br>(8.2)% | ( <b>754)</b><br>(9.1)%   | -2%<br>-90bps           | Research & Development expenditure As a % of sales         | (1,695)<br>(10.3)% | (1,510)<br>(8.7)% | -11%<br>-160bps |

| (20)   | 6      | -97%    | IFRS impact As a % of sales  | (132)  | <b>52</b> | na      |
|--------|--------|---------|--|--------|-----------|---------|
| 1.5%   | 0.1%   | -140bps |  | (0.8)% | 0.3%      | na      |
| 279    | 295    | +6%     | Capitalized development expenditure  As a % of sales                                   | 598    | 586       | -2%     |
| 3.0%   | 3.6%   | +60bps  |  | 3.6%   | 3.4%      | -20bps  |
| (299)  | (289)  | -3%     | Amortization and impairment of capitalized development expenditure(1)  As a % of sales | (730)  | (534)     | -27%    |
| (3.2)% | (3.5)% | -30bps  |  | (4.4)% | (3.1)%    | -130bps |

As a % of sales



\*Excl. JV & Associates NB: Rounded figures

| H2 2020                   | H2 2021            | <b>A</b>            |  | FY 2020            | FY 2021            | <b>A</b>               |
|---------------------------|--------------------|---------------------|--|--------------------|--------------------|------------------------|
| 9,378                     | 8,268              | -12%                | Total sales (€m)                       | 16,436             | 17,262             | +5%                    |
| <b>1,648</b> <i>17.6%</i> | <b>1,454</b> 17.6% | <b>-12%</b><br>Obps | Gross margin As a % of sales           | <b>2,155</b> 13.1% | <b>3,040</b> 17.6% | <b>+41%</b><br>+450bps |
| (767)<br>(8.2)%           | (754)<br>(9.1)%    | -2%<br>-90bps       | R&D expenditure As a % of sales        | (1,695)<br>(10.3)% | (1,510)<br>(8.7)%  | -11%<br>-160bps        |
| (413)<br>(4.4)%           | (416)<br>(5.0)%    | -1%<br>-60bps       | SG&A<br>As a % of sales                | (832)<br>(5.1)%    | (831)<br>(4.8)%    | 0%<br>-30bps           |
| 468                       | 284                | -39%                | Operating margin excl. JV & associates | (372)              | 699                | n.a.                   |
| 5.0%                      | 3.4%               | -160bps             | As a % of sales                        | (2.3)%             | 4.0%               | n.a.                   |
| (112)                     | (124)              | +11%                | JV & associates                        | (278)              | (243)              | -13%                   |
| (1.2)%                    | (1.5)%             | -30bps              | As a % of sales                        | (1.7)%             | (7.4)%             | +30bps                 |
| 356                       | 160                | -55%                | Operating margin incl. JV & associates | (650)              | 456                | n.a.                   |
| 3.8%                      | 1.9%               | -190bps             | As a % of sales                        | (4.0)%             | 2.6%               | n.a.                   |
| 1,303                     | 1,103              | -15%                | EBITDA                                 | 1,505              | 2,308              | +53%                   |
| 13.9%                     | 13.4%              | -50bps              | As a % of sales                        | 9.1%               | 13.4%              | +430bps                |

## **INCOME STATEMENT**

**FY 2021** 

|                        |                 | i                      |  |                       |                 | 1                       |
|------------------------|-----------------|------------------------|--|-----------------------|-----------------|-------------------------|
| H2 2020                | H2 2021         | <b>A</b>               |  | FY 2020               | FY 2021         | <b>A</b>                |
| 9,378                  | 8,268           | -12%                   | Total sales (€m)                                       | 16,436                | 17,262          | +5%                     |
| <b>356</b> 3.8%        | <b>160</b> 1.9% | <b>-55%</b><br>-190bps | Operating margin incl. JV & associates As a % of sales | <b>(650)</b> (4.0)%   | <b>456</b> 2.6% | n.a.                    |
| (72)<br>(0.8)%         | (21)<br>(0.3)%  | -71%<br>-50bps         | Other income & expenses As a % of sales                | (207)<br>(1.3)%       | (50)<br>(0.3)%  | -76%<br>-100bps         |
| 284<br>3.0%            | 139<br>1.7%     | -51%<br>-130bps        | Operating income As a % of sales                       | (857)<br>(5.2)%       | 406<br>2.4%     | n.a.                    |
| (34)                   | (32)            | -6%                    | Cost of net debt                                       | (67)                  | (60)            | -10%                    |
| 8                      | 90              | 8x                     | Other financial income & expenses                      | (14)                  | 96              | n.a.                    |
| 258                    | 197             | -24%                   | Income before taxes                                    | (938)                 | 442             | n.a.                    |
| (108)                  | (83)            | -23%                   | Income taxes   | (132)                 | (197)           | +49%                    |
| 29.2%                  | 25.9%           | -330bps                | Effective tax rate                                     | 20.0%                 | 28.8%           | +880bps                 |
| (24)                   | (29)            | +21%                   | Non-controlling interests and other                    | (19)                  | (70)            | -268%                   |
| <b>126</b> <i>1.3%</i> | <b>85</b> 1.0%  | <b>-33%</b><br>-30bps  | Net income As a % of sales                             | <b>(1,089)</b> (6.6)% | <b>175</b> 7.0% | <b>n.a.</b> <i>n.a.</i> |
| n.a.                   | n.a.            | n.a                    | EPS  | (4.55)                | 0.73            | n.a.                    |
| n.a.                   | n.a.            | n.a.                   | ROCE   | (13)%                 | 9%              | n.a.                    |
| n.a.                   | n.a.            | n.a.                   | ROA  | (12)%                 | 5%              | n.a.                    |

#### In €m and as a % of sales



<sup>\*</sup> Excl. Capitalized R&D



#### **FY 2021**

### FREE CASH FLOW STATEMENT

| H2 2020 | H2 2021 |                                      | FY 2020 | FY 2021 |
|---------|---------|--------------------------------------|---------|---------|
| 1,303   | 1,103   | EBITDA (€m)                          | 1,505   | 2,308   |
| 840     | (242)   | Change in operating working capital  | 266     | (460)   |
| 14      | (188)   | of which increase in inventories     | 218     | (370)   |
| (32)    | (24)    | Restructuring & social costs         | (62)    | (78)    |
| (153)   | (151)   | Other operating items (incl. taxes)  | (86)    | (369)   |
| (82)    | (104)   | of which: Taxes                      | (188)   | (237)   |
| (70)    | (77)    | Pensions                             | (86)    | (18)    |
| (43)    | (44)    | IFRS 16 leases                       | (86)    | (86)    |
| 1,958   | 686     | Cash from operating activities* (€m) | 1,623   | 1,401   |
| (336)   | (244)   | PP&E CAPEX                           | (731)   | (523)   |
| (279)   | (295)   | Capitalized R&D                      | (598)   | (586)   |
| 1,343   | 147     | Free cash flow* (€m)                 | 294     | 292     |
| (13)    | (15)    | Interest                             | (75)    | (28)    |
| (141)   | (232)   | Other financial items                | (302)   | (416)   |
| 1,189   | (100)   | Net cash flow (€)                    | (83)    | (152)   |
| 2,944   | 3,104   | Net debt (€m)                        | 2,944   | 3,104   |




#### **LEVERAGE RATIO OF 1.34x EBITDA**


#### **Net debt to EBITDA**



#### Covenant of 3.5x




#### Shareholders' equity and net debt



|         | LT   | Outlook | ST      |
|---------|------|---------|---------|
| Moody's | Baa3 | Stable  | Prime-3 |
| S&P     | BB+  | Stable  | В       |

#### **CASH & DEBT PROFILE**




#### **ORDER INTAKE**

Order intake & book to bill


## Valeo SIEMENS e Automotive €1.1bn €18.9bn €21.0bn Valeo Book to bill Book to bill 1.5x 1.4x 2020 2021

Percentage of innovative products in 2021



\*Products and technologies sold by less than 3 years excl. Valeo Siemens eAutomotive


#### OEM sales of €14.4bn



|                | Order intake/<br>OEM sales ratio |
|----------------|----------------------------------|
| Asia           | 1.3x                             |
| of which China | 1.4x                             |
| Europe         | 1.6x                             |
| North America  | 1.5x                             |
| South America  | 0.7x                             |
| Group          | 1.5x                             |

#### % of 2021 OEM sales\*

#### Order intake of €21bn



% of 2021 order intake\*

\*OEM sales and order intake by destination incl. joint ventures but excl. Valeo Siemens eAutomotive

# DIVIDEND OF €0.35 PER SHARE UP 17%

TO BE PROPOSED AT THE NEXT AGM

#### **GUIDANCE 2022**

In 2022, Valeo will focus its efforts on integrating Valeo Siemens eAutomotive, implementing its efficiency program and managing the impacts of inflation.

Based on IHS annual automotive production estimates (released in February 2022), reduced by 1.5%, corresponding to around 82.9 million vehicles (with slight growth in the first half of 2022 and growth of more than 10% in the second half), Valeo has set the following objectives:

|                                    | 2022*         |
|------------------------------------|---------------|
| Sales (in €bn)                     | 19.2 - 20.0   |
| EBITDA (As a % of sales)           | 11.8% - 12.3% |
| Operating margin (As a % of sales) | 3.2% - 3.7%   |
| Free cash flow (in €m)             | ~320          |

<sup>\*</sup> Based on the integration of Valeo Siemens eAutomotive after July 2022 following the acquisition by Valeo of the 50% stake held by Siemens in the joint venture. The transaction is subject to authorization from the relevant antitrust authorities and the relevant employee representative bodies will be informed and consulted.

These objectives do not take into account the potentially unfavorable impacts of recent developments in the Russia-Ukraine crisis on the economic and financial environment, such as a decline in production volumes or an increase in energy or raw material prices to above those seen in early 2022.

The impacts of applying IAS 37 revised and IFRS 3 in connection with the accounting for the Valeo Siemens eAutomotive acquisition will be presented at a later date.

# **ESG**

#### STRONG ESG PRACTICES IN AUTOMOTIVE INDUSTRY WITH AMBITIOUS TARGETS







- Carbon neutrality on the 3 scopes by 2050<sup>(1)</sup>
- Intermediate CO2ea reduction **target of -45%** by 2030<sup>(2)</sup> without offsetting
  - Including Scope 3 downstream, the end-use of our products 50%<sup>(3)</sup> net reduction target by 2030
- Improve our eco-efficiency and resource allocation by 2025<sup>(2)</sup>
  - **Energy** as % of sales by -6%
  - Waste as % of sales by -9%
  - Water as % of sales by -6%

- Employee safety as #1 priority with Accident Frequency Rate < 1.7 by 2025
- **Promote diversity** 
  - Share of women in new hires of 35%
  - Increase % plants run by local manager to 80% by 2025
- **Encourage talent development &** well-being at work
- Integration of suppliers in sustainability approach
  - Target of 82% of total purchases subject to sustainability assessment by 2025

- Separation of roles of Chairman and CEO roles in January 2022
- Board independence with 83%<sup>(4)</sup> of directors independent
- Board diversity with 50%<sup>(5)</sup> of Board members women
- Top management compensation includes CSR criteria
  - ...also sustainability criteria included in variable compensation of 1,500 managers since 2021
- **Ethics & business practices** 
  - Compliance Officer reports directly to CEO (best practice)
  - Speak-up culture

VALEO RESERVED


<sup>(3)</sup> NET 2030 Valeo target =SBTi absolute value + additional 2030 CO2 reduction yearly realised vs 2019 baseline thanks to Valeo electrification portfolio



<sup>(1)</sup> Scopes 1, 2 & 3 upstream


<sup>(2)</sup> vs. 2019 baseline

# **BACKUP SLIDES**




#### **OEM SALES PENALIZED BY PRODUCTION DISRUPTIONS**

H2 2021 vs 2020




\*IHS as of February 14, 2022/CPCA estimates for China



### **OEM SALES PENALIZED BY PRODUCTION DISRUPTIONS**

Q4 2021 vs 2020



<sup>\*</sup>IHS as of February 14, 2022/CPCA estimates for China

## RECONCILIATION OF VALEO AND TOP COLUMN MODULE (TCM) DATA

The Group decided to withdraw from the TCM Segment.

The table below reconciles reported consolidated data excluding the TCM business.

|  |                   | 2021    | TCM*   | 2021 excl.<br>TCM |
|--|-------------------|---------|--------|-------------------|
| Sales  | (In €m)           | 17,262  | 199    | 17,063            |
| Gross margin                                 | (In €m)           | 3,040   | 10     | 3,030             |
|  | (As a % of sales) | 17.6%   | 5.0%   | 17.8%             |
| R&D expenditure                              | (In €m)           | (1,510) | (18)   | (1,492)           |
|  | (As a % of sales) | (8.7)%  | (9.0)% | (8.7)%            |
| Selling & administrative expenses            | (In €m)           | (831)   | (11)   | (820)             |
|  | (As a % of sales) | (4.8)%  | (5.5)% | (4.8)%            |
| Operating margin excl. share in net earnings | (In €m)           | 699     | (19)   | 718               |
| (losses) of equity-accounted companies       | (As a % of sales) | 4.0%    | (9.5)% | 4.2%              |

<sup>\*</sup>Including intercompany transactions

### **SEGMENT INFORMATION**

| 2021   | Comfort & Driving      |                       |                    |                       |       |         |
|--|------------------------|-----------------------|--------------------|-----------------------|-------|---------|
| (€m)   | Assistance<br>Systems* | Powertrain<br>Systems | Thermal<br>Systems | Visibility<br>Systems | Other | Total   |
| Sales:   |                        |                       |                    |                       |       |         |
| <ul> <li>segment (excluding Group)</li> </ul>                  | 3,396                  | 4,528                 | 3,869              | 5,038                 | 263   | 17,093  |
| <ul><li>intersegment (Group)</li></ul>                         | 21                     | 123                   | 57                 | 56                    | (89)  | 169     |
| EBITDA   | 587                    | 566                   | 428                | 675                   | 52    | 2,308   |
| Research & Development expenditure, net                        | (554)                  | (299)                 | (253)              | (359)                 | (45)  | (1,510) |
| Investments in property, plant & equipment & intangible assets | 494                    | 306                   | 264                | 406                   | 95    | 1,565   |
| Segment assets   | 2,848                  | 3,310                 | 2,671              | 2,862                 | 290   | 11,98   |

| <u>2020</u> (€m)   | Comfort &<br>Driving<br>Assistance<br>Systems* | Powertrain<br>Systems | Thermal<br>Systems | Visibility<br>Systems | Other | Total   |
|--|--|-----------------------|--------------------|-----------------------|-------|---------|
| Sales:   | - Cyclome                                      |                       | <b>-</b>           | - Cyotome             |       | 1000    |
| <ul> <li>segment (excluding Group)</li> </ul>                  | 3,204  | 4,223                 | 3,650              | 4,957                 | 402   | 16,436  |
| • intersegment (Group)   | 24   | 147                   | 53                 | 67                    | (291) | 0       |
| EBITDA   | 412  | 409                   | 247                | 435                   | (2)   | 1,505   |
| Research & Development expenditure, net                        | (676)  | (287)                 | (275)              | (422)                 | (355) | (1,695) |
| Investments in property, plant & equipment & intangible assets | 389  | 344                   | 362                | 424                   | 39    | 1,558   |
| Segment assets   | 2,548  | 3,317                 | 2,586              | 2,830                 | 181   | 11,462  |

<sup>\*</sup>excl. TCM

#### **GLOSSARY**

- Order intake corresponds to business awarded by automakers during the period to Valeo, and to joint ventures and associates based on Valeo's share in net equity, (except Valeo Siemens eAutomotive, for which 100% of orders are taken into account), less any cancellations, based on Valeo's best reasonable estimates in terms of volumes, selling prices and project lifespans. Unaudited indicator.
- Like for like (or LFL): the currency impact is calculated by multiplying sales for the current period by the exchange rate for the previous period. The Group structure impact is calculated by (i) eliminating, for the current period, sales of companies acquired during the period, (ii) adding to the previous period full-year sales of companies acquired in the previous period, and (iii) eliminating, for the current period and for the comparable period, sales of companies sold during the current or comparable period.
- Operating margin including share in net earnings of equity-accounted companies corresponds to operating income before other income and expenses.
- ROCE, or return on capital employed, corresponds to operating margin (including share in net earnings of equity-accounted companies) divided by capital employed (including investments in equity-accounted companies), excluding goodwill.
- ROA, or return on assets, corresponds to operating income divided by capital employed (including investments in equity-accounted companies), including goodwill.
- **EBITDA** corresponds to (i) operating margin before depreciation, amortization and impairment losses (included in the operating margin) and the impact of government subsidies and grants on non-current assets, and (ii) net dividends from equity-accounted companies.
- Free cash flow corresponds to net cash from operating activities (excluding changes in non-recurring sales of receivables and payments for the principal portion of lease liabilities) after taking into account acquisitions and disposals of property, plant and equipment and intangible assets.
- Net cash flow corresponds to free cash flow less (i) cash flows in respect of investing activities, relating to acquisitions and disposals of investments and to changes in certain items shown in non-current financial assets, (ii) cash flows in respect of financing activities, relating to dividends paid, treasury share purchases and sales, interest paid and received, and acquisitions of equity interests without a change in control, and (iii) changes in non-recurring sales of receivables.
- Net debt comprises all long-term debt, liabilities associated with put options granted to holders of non-controlling interests, short-term debt and bank overdrafts, less loans and other long-term financial assets, cash and cash equivalents and the fair value of derivative instruments hedging the foreign currency and interest rate risks associated with these items.

## **INVESTOR RELATIONS VALEO** 100, rue de Courcelles F-75017 Paris France **Thierry Lacorre** E-mail: valeo.corporateaccess.mailbox@valeo.com Website: www.valeo.com

## **CONTACTS**

#### SHARE INFORMATION

#### Share Data

Bloomberg TickerReuters TickerFR FPVLOF.PA

• ISIN Number FR 0013176526

· Shares outstanding as of December 31,, 2021 242,574,781

#### **ADR Data**

Ticker/trading symbol
 VLEEY

· CUSIP Number 919134304

• Exchange OTC

· Ratio (ADR: ord)

Depositary BankJ.P. Morgan

· Contact at J.P. Morgan – ADR Jim Reeves

Broker relationship desk +1 212-622-2710

#### SAFE HARBOUR STATEMENT

Statements contained in this document, which are not historical fact, constitute "forward-looking statements". These statements include projections and estimates and their underlying assumptions, statements regarding projects, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Even though Valeo's Management feels that the forward-looking statements are reasonable as at the date of this document, investors are put on notice that the forward-looking statements are subject to numerous factors, risks and uncertainties that are difficult to predict and generally beyond Valeo's control, which could cause actual results and events to differ materially from those expressed or projected in the forward-looking statements. Such factors include, among others, the Company's ability to generate cost savings or manufacturing efficiencies to offset or exceed contractually or competitively required price reductions. The risks and uncertainties to which Valeo is exposed mainly comprise the risks resulting from the investigations currently being carried out by the antitrust authorities as identified in the Universal Registration Document, risks which relate to being a supplier in the automotive industry and to the development of new products and risks due to certain global and regional economic conditions. It is also exposed to environmental and industrial risks, risks associated with the Covid-19 epidemic, including risks related to the Group's supply of electronic components and the rise in raw material prices, as well as risks and uncertainties described or identified in the public documents submitted by Valeo to the French financial markets authority (*Autorité des marchés financiers* – AMF), including those set out in the "Risk Factors" section of the 2020 Universal Registration Document registered with the AMF on April 6, 2021 (under number D.21-0260).

The Company assumes no responsibility for any analyses issued by analysts and any other information prepared by third parties which may be used in this document. Valeo does not intend or assume any obligation to review or to confirm the estimates issued by analysts or to update any forward-looking statements to reflect events or circumstances which occur subsequent to the date of this document.



SMART TECHNOLOGY FOR SMARTER MOBILITY